Advanced Medical Solutions Grp PLC
6 April 2000
ADVANCED MEDICAL SOLUTIONS GROUP PLC SIGNS DISTRIBUTION
AGREEMENT WITH NOVARTIS CONSUMER HEALTH
Winsford, 6 April 2000: Advanced Medical Solutions Group plc (AMS), today
announced the signing of an agreement with Novartis Consumer Health, Europe,
for the distribution of its ActivHeal(TM) range of innovative wound
dressings into the third largest consumer healthcare market, Germany.
This is the second such agreement with Novartis Consumer Health; in January
of this year a similar agreement covering UK and Ireland was signed. AMS now
has distribution in the majority of the key world-wide consumer healthcare
markets.
Commenting on the agreement, Don Evans, Chief Executive of AMS, said:
'We are very pleased with this extension of our association with Novartis
Consumer Health; their continued interest confirms the leadership position
AMS has established developing the market for advanced First Aid products.'
Michael Orsinger, Regional Director of Europe, Novartis Consumer Health,
added:
'We are delighted to be able to add the advanced first aid range of
woundcare products to the Fenistil brand in Germany and look forward to
developing further our relationship with AMS.'
Advanced Medical Solutions is one of the leading global companies in the
development and manufacture of products for the advanced wound-care market
which is currently estimated to be in excess of US$1 billion world-wide
(1999).
Novartis is a world leader in healthcare with core businesses in
pharmaceuticals, consumer health, generics, eye-care, and animal health. In
1999, the Group (including Agribusiness) achieved sales of CHF 32.4 billion.
Enquiries:
Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer Tel: 01606 863500
Mary Tavener, Group Finance Director
Gavin Anderson & Co
Philip Ward / Charlotte Stone Tel: 0171 457 2345
Further information on Advanced Medical Solutions can be found at
www.admedsol.com
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.